| Contributing Factors | HIV status | Total n (%) | χ2 | df | p value | ||||||
| Negative n (%) | Positive n (%) | ||||||||||
| Starting of Antenatal Visits | |||||||||||
| 0 - 3 months | 43 (51.8%) | 3 (23.1%) | 46 (47.9%) | 4.477 | 3 | 0.214 | |||||
| 4 - 6 months | 28 (33.7%) | 8 (61.5%) | 36 (37.5%) | ||||||||
| 7 - 9 months | 8 (9.6%) | 1 (7.7%) | 9 (9.4%) | ||||||||
| Didn’t attend clinics | 4 (4.8%) | 1 (7.7%) | 5 (5.2%) | ||||||||
| HIV Testing with Current Infant | |||||||||||
| During pregnancy (ANC visits) | 48 (57.8%) | 4 (30.8%) | 52 (54.2%) | 10.711 | 5 | 0.057 | |||||
| During labour | 8 (9.6%) | 1 (7.7%) | 9 (9.4%) | ||||||||
| After delivery | 7 (8.4%) | 3 (23.1%) | 10 (10.4%) | ||||||||
| Voluntary counselling and testing | 19 (22.9%) | 4 (30.8%) | 23 (24.0%) | ||||||||
| Home visit | 1 (1.2%) | 0 (0.0%) | 1 (1.00%) | ||||||||
| In the ward | 0 (0.0%) | 1 (7.7%) | 1 (1.0%) | ||||||||
| Maternal PMTCT Intervention | |||||||||||
| Already in ART | 37 (44.6%) | 3 (23.1%) | 40 (41.7%) | 6.142 | 4 | 0.189 | |||||
| Single dose Nevirapine | 4 (4.8%) | 0 (0%) | 4 (4.2%) | ||||||||
| Single dose Nevirapine + AZT | 3 (3.6%) | 2 (15.6%) | 5 (5.2%) | ||||||||
| SD NVP + 3TC + AZT | 3 (3.6%) | 0 (0%) | 3 (3.1%) | ||||||||
| Septrin + Multivitamin | 36 (43.4%) | 8 (61.5%) | 44 (45.8%) | ||||||||
| Place of Delivery | |||||||||||
| At home | 4 (4.8%) | 5 (38.5%) | 9 (9.4%) | 29.389 | 2 | 0.001 | |||||
| Health facility | 79 (95.2%) | 6 (46.2%) | 85 (88.5%) | ||||||||
| On the way to hospital | 0 (0%) | 2 (12.5%) | 2 (2.1%) | ||||||||
| ARV Prophylaxis at Birth | |||||||||||
| Received ARV Prophylaxis | 78 (94.0%) | 5 (38.5%) | 83 (86.5%) | 29.586 | 1 | 0.0001 | |||||
| Did not receive ARV prophylaxis | 5 (6.0%) | 8 (61.5%) | 13 (13.5%) | ||||||||